{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:01:28Z","timestamp":1772121688855,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.repc.2020.03.015","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:01:43Z","timestamp":1598659303000},"page":"517-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review"],"prefix":"10.1016","volume":"39","author":[{"given":"C\u00e2ndida","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulce","family":"Brito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia","family":"Branco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Miguel","family":"Fraz\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Silva-Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Bettencourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2020.03.015_bib0455","first-page":"2129","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J."},{"key":"10.1016\/j.repc.2020.03.015_bib0460","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.repc.2019.09.006","article-title":"Current costs of heart failure in Portugal and expected increases due to population aging","volume":"39","author":"Gouveia","year":"2020","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0465","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ehf2.12399","article-title":"The current and future burden of heart failure in Portugal","volume":"6","author":"Gouveia","year":"2019","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0470","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.repc.2017.11.010","article-title":"Heart failure in numbers: estimates for the 21st century in Portugal","volume":"37","author":"Fonseca","year":"2018","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0475","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0480","unstructured":"National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults: diagnosis and management. London, UK: National Institute for Health and Care Excellence; 2018. Available at: nice.org.uk\/guidance\/ng106.[accessed 16 May 2019]."},{"key":"10.1016\/j.repc.2020.03.015_bib0485","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0490","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0495","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.repc.2020.03.015_bib0500","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2020.03.015_bib0505","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.repc.2020.03.015_bib0510","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ejhf.1079","article-title":"Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF","volume":"20","author":"Beusekamp","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0515","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2710.2003.00491.x","article-title":"The safety of spironolactone treatment in patients with heart failure","volume":"28","author":"Anton","year":"2003","journal-title":"J Clin Pharm Ther."},{"key":"10.1016\/j.repc.2020.03.015_bib0520","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0525","doi-asserted-by":"crossref","first-page":"e003316","DOI":"10.1161\/CIRCHEARTFAILURE.116.003316","article-title":"Heart failure, diabetes mellitus, and chronic kidney disease: a clinical conundrum","volume":"9","author":"Aguilar","year":"2016","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0530","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ejhf.210","article-title":"Impact of worsening renal function related to medication in heart failure","volume":"17","author":"Brunner-La Rocca","year":"2015","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0535","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.amjcard.2016.08.078","article-title":"Serum potassium levels and outcome in patients with chronic heart failure","volume":"118","author":"Hoss","year":"2016","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0540","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit Care."},{"key":"10.1016\/j.repc.2020.03.015_bib0545","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0550","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurjhf\/hfs145","article-title":"Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial","volume":"14","author":"Kiernan","year":"2012","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0555","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0560","first-page":"s307","article-title":"The burden of hyperkalemia in patients with cardiovascular and renal disease","volume":"21","author":"Dunn","year":"2015","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.repc.2020.03.015_bib0565","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension."},{"key":"10.1016\/j.repc.2020.03.015_bib0570","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","article-title":"Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system","volume":"245","author":"Nilsson","year":"2017","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0575","doi-asserted-by":"crossref","first-page":"e31082","DOI":"10.1371\/journal.pone.0031082","article-title":"Physician and patient predictors of evidence-based prescribing in heart failure: a multilevel study","volume":"7","author":"Peters-Klimm","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.repc.2020.03.015_bib0580","doi-asserted-by":"crossref","first-page":"e012818","DOI":"10.1136\/bmjopen-2016-012818","article-title":"Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study","volume":"7","author":"Schmidt","year":"2017","journal-title":"BMJ Open."},{"key":"10.1016\/j.repc.2020.03.015_bib0585","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","article-title":"The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure","volume":"46","author":"Shah","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0590","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0595","first-page":"709","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"Randomized Aldactone Evaluation Study Investigators. N Engl J Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0600","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0605","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0002-8703(96)90365-8","article-title":"Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"131","author":"Kostis","year":"1996","journal-title":"SOLVD Investigators. Am Heart J."},{"key":"10.1016\/j.repc.2020.03.015_bib0610","first-page":"1","article-title":"Kidney disease: Improving global outcomes (KDIGO) CKD work group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney International Supplements."},{"key":"10.1016\/j.repc.2020.03.015_bib0615","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0620","unstructured":"Centre for Reviews and Dissemination. Systematic reviews. CRD's guidance for undertaking reviews in health care. York, UK: University of York; 2009. Available at: http:\/\/www.york.ac.uk\/inst\/crd\/index_guidance.htm [accessed 1 May 2018]."},{"key":"10.1016\/j.repc.2020.03.015_bib0625","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/pds.3748","article-title":"Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor\/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort","volume":"24","author":"Abbas","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.repc.2020.03.015_bib0630","first-page":"449","article-title":"Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure","volume":"6","author":"Anand","year":"2010","journal-title":"Vasc Health Risk Manag."},{"key":"10.1016\/j.repc.2020.03.015_bib0635","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial","volume":"167","author":"Bowling","year":"2013","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.30.1.1","article-title":"Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure","volume":"30","author":"Cavallari","year":"2010","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.repc.2020.03.015_bib0645","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jcma.2017.04.011","article-title":"Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry","volume":"80","author":"Chang","year":"2017","journal-title":"J Chin Med Assoc."},{"key":"10.1016\/j.repc.2020.03.015_bib0650","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjcvp\/pvu010","article-title":"ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry","volume":"1","author":"De Blois","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.repc.2020.03.015_bib0655","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2006.05.030","article-title":"Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials","volume":"152","author":"de Denus","year":"2006","journal-title":"Am Heart J."},{"key":"10.1016\/j.repc.2020.03.015_bib0660","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejim.2015.12.007","article-title":"Therapy modifications during hospitalization in patients with chronic heart failure","volume":"29","author":"Deticek","year":"2016","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0665","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2020.03.015_bib0670","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ahj.2016.03.024","article-title":"Long-term changes of renal function in relation to ace inhibitor\/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease","volume":"178","author":"Frohlich","year":"2016","journal-title":"Am Heart J."},{"key":"10.1016\/j.repc.2020.03.015_bib0675","first-page":"6","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","author":"Gilstrap","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.repc.2020.03.015_bib0680","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/106286060301800205","article-title":"Analysis of a large cohort of health maintenance organization patients with congestive heart failure","volume":"18","author":"Gladowski","year":"2003","journal-title":"Am J Med Qual."},{"key":"10.1016\/j.repc.2020.03.015_bib0685","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejim.2011.04.008","article-title":"Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic","volume":"22","author":"Goland","year":"2011","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0690","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00005344-199710000-00020","article-title":"Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure","volume":"30","author":"Hamroff","year":"1997","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.repc.2020.03.015_bib0695","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"Hernandez","year":"2012","journal-title":"JAMA."},{"key":"10.1016\/j.repc.2020.03.015_bib0700","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000457946","article-title":"Discontinuation\/dose reduction of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers during acute decompensated heart failure in African-American patients with reduced left-ventricular ejection fraction","volume":"137","author":"Kane","year":"2017","journal-title":"Cardiology."},{"key":"10.1016\/j.repc.2020.03.015_bib0705","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cardfail.2006.01.003","article-title":"Appropriateness of spironolactone prescribing in heart failure patients: a population-based study","volume":"12","author":"Ko","year":"2006","journal-title":"J Card Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0710","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ejhf.887","article-title":"Physicians\u2019 guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0715","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.repc.2020.03.015_bib0720","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-11-4","article-title":"Use, tolerability and compliance of spironolactone in the treatment of heart failure","volume":"11","author":"Lachaine","year":"2011","journal-title":"BMC Clin Pharmacol."},{"key":"10.1016\/j.repc.2020.03.015_bib0725","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.amjcard.2013.06.039","article-title":"Effectiveness and safety of spironolactone for systolic heart failure","volume":"112","author":"Lee","year":"2013","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0730","first-page":"94","article-title":"Hyperkalemia during spironolactone use in patients with decompensated heart failure","volume":"91","author":"Lima","year":"2008","journal-title":"Arq Bras Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0735","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/clc.20284","article-title":"Safety of spironolactone use in ambulatory heart failure patients","volume":"31","author":"Lopes","year":"2008","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0740","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ejhf.226","article-title":"Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice","volume":"17","author":"Michel","year":"2015","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0745","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00392-009-0011-7","article-title":"Effects of candesartan cilexetil \u201cadd-on\u201d treatment in congestive heart failure outpatients in daily practice","volume":"98","author":"Mitrovic","year":"2009","journal-title":"Clin Res Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0750","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.amjcard.2011.10.027","article-title":"Frequency and predictors of hyperkalemia in patients >\/=60 years of age with heart failure undergoing intense medical therapy","volume":"109","author":"Muzzarelli","year":"2012","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0755","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00392-007-0617-6","article-title":"Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy","volume":"97","author":"Peters-Klimm","year":"2008","journal-title":"Clin Res Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0760","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2020.03.015_bib0765","first-page":"S2","article-title":"Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure","volume":"23","author":"Polson","year":"2017","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.repc.2020.03.015_bib0770","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","author":"Investigators","year":"1996","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0775","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ijcard.2014.02.034","article-title":"Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study","volume":"173","author":"Rossignol","year":"2014","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0780","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1053\/euhj.2000.2311","article-title":"Efficacy safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk including those with diabetes mellitus. Results from the ATLAS","volume":"21","author":"Ryden","year":"2000","journal-title":"Eur Heart trial.J."},{"key":"10.1016\/j.repc.2020.03.015_bib0785","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/j.ijcard.2014.01.002","article-title":"Assessment of guideline adherence in hospitalised heart failure patients with systolic dysfunction in Dubai","volume":"172","author":"Saheb Sharif-Askari","year":"2014","journal-title":"United Arab Emirates. Int J Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0790","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2710.2006.00772.x","article-title":"Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil","volume":"31","author":"Saito","year":"2006","journal-title":"J Clin Pharm Ther."},{"key":"10.1016\/j.repc.2020.03.015_bib0795","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2710.2005.00694.x","article-title":"Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil","volume":"30","author":"Saito","year":"2005","journal-title":"J Clin Pharm Ther."},{"key":"10.1016\/j.repc.2020.03.015_bib0800","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"Randomized controlled study of finerenone A. eplerenone in Japanese patients with worsening chronic heart failure vs. diabetes \/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J."},{"key":"10.1016\/j.repc.2020.03.015_bib0805","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0810","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis","volume":"18","author":"Solomon","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0815","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0b013e3182a3e525","article-title":"Reasons for not prescribing guideline-recommended medications to adults with heart failure","volume":"51","author":"Steinman","year":"2013","journal-title":"Med Care."},{"key":"10.1016\/j.repc.2020.03.015_bib0820","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?","volume":"10","author":"Svensson","year":"2004","journal-title":"J Card Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0825","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","article-title":"Spironolactone-induced renal insufficiency hyperkalemia in patients with heart failure","volume":"148","author":"Tamirisa","year":"2004","journal-title":"Am Heart J."},{"key":"10.1016\/j.repc.2020.03.015_bib0830","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/CIRCHEARTFAILURE.113.000530","article-title":"Race influences the safety and efficacy of spironolactone in severe heart failure","volume":"6","author":"Vardeny","year":"2013","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0835","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0840","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2125.2004.02187.x","article-title":"Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message","volume":"58","author":"Witham","year":"2004","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.repc.2020.03.015_bib0845","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2020.03.015_bib0850","doi-asserted-by":"crossref","first-page":"78C","DOI":"10.1016\/0002-9149(92)91362-8","article-title":"Comparison of treatment with lisinopril versus enalapril for congestive heart failure","volume":"70","author":"Zannad","year":"1992","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.repc.2020.03.015_bib0855","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0860","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1093\/eurheartj\/suy028","article-title":"Hyperkalaemia: aetiology, epidemiology, and clinical significance","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur Heart J Suppl."},{"key":"10.1016\/j.repc.2020.03.015_bib0865","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archinte.161.2.177","article-title":"Impact of a guideline-based disease management team on outcomes of hospitalized patients with congestive heart failure","volume":"161","author":"Costantini","year":"2001","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0870","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0875","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0880","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens."},{"key":"10.1016\/j.repc.2020.03.015_bib0885","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0890","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2020.03.015_bib0895","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2020.03.015_bib0900","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail."}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255120303474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255120303474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:08:47Z","timestamp":1760108927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255120303474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":90,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0870255120303474"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2020.03.015","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2020.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}